The Vaccinia Virus Based Sementis Copenhagen Vector Vaccine Against Zika and Chikungunya is Immunogenic in Non-human Primates

Overview

Journal NPJ Vaccines

Date 2020 Jun 19

PMID 32550013

Citations 10

Authors

Natalie A Prow

Liang Liu

Mary K McCarthy

Kevin Walters

Raj Kalkeri

Jillian Geiger

Fusataka Koide

Tamara H Cooper

Preethi Eldi

Eri Nakayama

Kerrilyn R Diener

Paul M Howley

John D Hayball

Thomas E Morrison

Andreas Suhrbier

Affiliations

Soon will be listed here.

Abstract

The Sementis Copenhagen Vector (SCV) is a new vaccinia virus-derived, multiplication-defective, vaccine technology assessed herein in non-human primates. Indian rhesus macaques () were vaccinated with a multi-pathogen recombinant SCV vaccine encoding the structural polyproteins of both Zika virus (ZIKV) and chikungunya virus (CHIKV). After one vaccination, neutralising antibody responses to ZIKV and four strains of CHIKV, representative of distinct viral genotypes, were generated. A second vaccination resulted in significant boosting of neutralising antibody responses to ZIKV and CHIKV. Following challenge with ZIKV, SCV-ZIKA/CHIK-vaccinated animals showed significant reductions in viremias compared with animals that had received a control SCV vaccine. Two SCV vaccinations also generated neutralising and IgG ELISA antibody responses to vaccinia virus. These results demonstrate effective induction of immunity in non-human primates by a recombinant SCV vaccine and illustrates the utility of SCV as a multi-disease vaccine platform capable of delivering multiple large immunogens.

Citing Articles

Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA-14-2.

Song B, Frank J, Yun S, Julander J, Mason J, Polejaeva I Int J Mol Sci. 2025; 26(1.

PMID: 39796052 PMC: 11720029. DOI: 10.3390/ijms26010195.

Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.

Rawle D, Hugo L, Cox A, Devine G, Suhrbier A Nat Rev Immunol. 2024; 24(9):621-636.

PMID: 38570719 DOI: 10.1038/s41577-024-01016-6.

Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.

Wang Y Viruses. 2023; 15(8).

PMID: 37632084 PMC: 10457812. DOI: 10.3390/v15081742.

Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.

Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J Nat Commun. 2023; 14(1):3035.

PMID: 37236967 PMC: 10213590. DOI: 10.1038/s41467-023-38651-x.

Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells.

Abbo S, Nguyen W, Abma-Henkens M, van de Kamer D, Savelkoul N, Geertsema C J Virol. 2023; 97(3):e0160122.

PMID: 36883812 PMC: 10062127. DOI: 10.1128/jvi.01601-22.

References

Goo L, Dowd K, Lin T, Mascola J, Graham B, Ledgerwood J . A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. J Infect Dis. 2016; 214(10):1487-1491. PMC: 5091377. DOI: 10.1093/infdis/jiw431. View

Meng X, Kaever T, Yan B, Traktman P, Zajonc D, Peters B . Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets. Virology. 2018; 518:284-292. PMC: 5911218. DOI: 10.1016/j.virol.2018.03.005. View

Leon A, David A, Madeline B, Guianvarch L, Dureau E, Champion-Arnaud P . The EB66® cell line as a valuable cell substrate for MVA-based vaccines production. Vaccine. 2016; 34(48):5878-5885. DOI: 10.1016/j.vaccine.2016.10.043. View

Pittman P, Hahn M, Lee H, Koca C, Samy N, Schmidt D . Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. N Engl J Med. 2019; 381(20):1897-1908. DOI: 10.1056/NEJMoa1817307. View

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U . A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One. 2018; 13(2):e0192312. PMC: 5819775. DOI: 10.1371/journal.pone.0192312. View

Abbink P, Stephenson K, Barouch D . Zika virus vaccines. Nat Rev Microbiol. 2018; 16(10):594-600. PMC: 6162149. DOI: 10.1038/s41579-018-0039-7. View

Suhrbier A . Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev Rheumatol. 2019; 15(10):597-611. DOI: 10.1038/s41584-019-0276-9. View

Lopez-Camacho C, Kim Y, Abbink P, Larocca R, Huiskonen J, Barouch D . Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers. Pathogens. 2019; 8(4). PMC: 6963679. DOI: 10.3390/pathogens8040216. View

Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X . Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Elife. 2013; 2:e00435. PMC: 3614025. DOI: 10.7554/eLife.00435. View

10.

Hassert M, Harris M, Brien J, Pinto A . Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection. Front Immunol. 2019; 10:1678. PMC: 6652237. DOI: 10.3389/fimmu.2019.01678. View

11.

Lauer K, Borrow R, Blanchard T . Multivalent and Multipathogen Viral Vector Vaccines. Clin Vaccine Immunol. 2016; 24(1). PMC: 5216423. DOI: 10.1128/CVI.00298-16. View

12.

Richner J, Diamond M . Zika virus vaccines: immune response, current status, and future challenges. Curr Opin Immunol. 2018; 53:130-136. PMC: 6141315. DOI: 10.1016/j.coi.2018.04.024. View

13.

Kam Y, Lum F, Teo T, Lee W, Simarmata D, Harjanto S . Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med. 2012; 4(4):330-43. PMC: 3376860. DOI: 10.1002/emmm.201200213. View

14.

Terzian A, Schanoski A, Mota M, Alves da Silva R, Estofolete C, Colombo T . Viral Load and Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed Zika Virus-Infected Patients. Clin Infect Dis. 2017; 65(8):1260-1265. PMC: 5849103. DOI: 10.1093/cid/cix558. View

15.

Goh L, Hobson-Peters J, Prow N, Gardner J, Bielefeldt-Ohmann H, Pyke A . Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin Immunol. 2013; 149(3):487-97. DOI: 10.1016/j.clim.2013.10.004. View

16.

Cardoso C, Kikuti M, Prates A, Paploski I, Tauro L, Silva M . Unrecognized Emergence of Chikungunya Virus during a Zika Virus Outbreak in Salvador, Brazil. PLoS Negl Trop Dis. 2017; 11(1):e0005334. PMC: 5289630. DOI: 10.1371/journal.pntd.0005334. View

17.

Prow N, Jimenez Martinez R, Hayball J, Howley P, Suhrbier A . Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines. Expert Rev Vaccines. 2018; 17(10):925-934. DOI: 10.1080/14760584.2018.1522255. View

18.

Gray E, Madiga M, Hermanus T, Moore P, Wibmer C, Tumba N . The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011; 85(10):4828-40. PMC: 3126191. DOI: 10.1128/JVI.00198-11. View

19.

Broeckel R, Haese N, Messaoudi I, Streblow D . Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model). Pathogens. 2015; 4(3):662-81. PMC: 4584280. DOI: 10.3390/pathogens4030662. View

20.

Chu H, Das S, Fuchs J, Suresh M, Weaver S, Stinchcomb D . Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine. 2013; 31(33):3353-60. PMC: 3731778. DOI: 10.1016/j.vaccine.2013.05.059. View